SG

Sight Sciences IncNASDAQ SGHT Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.328

Micro

Exchange

XNAS - Nasdaq

SGHT Stock Analysis

SG

Uncovered

Sight Sciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-15/100

Low score

Market cap $B

0.328

Dividend yield

Shares outstanding

48.419 B

Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. It sells both systems through a direct sales model.

View Section: Eyestock Rating